Abstract

The development of anti-vascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. Ocular angiogenesis and macular oedema are the major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage and scarring. Anti-VEGF agents are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this session, we will explore the current use of anti-VEGF in a variety of retinal diseases like Age related macular degeneration, diabetic retinopathy, retinal vascular occlusion, pachychoroid diseases. We shall also discuss the complications of Anti-VEGF agents, the newer drug delivery systems and the impact that these medications have had on the visual outcome for patients.

Talks